Brief: Matinas Biopharma Initiates Dosing In Phase 1 Study Of Potential First Oral Aminoglycoside Antibiotic Drug Mat2501
21/10/2021 12:48
Oct 21 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA INITIATES DOSING IN PHASE 1 STUDY OF
POTENTIAL
FIRST ORAL AMINOGLYCOSIDE ANTIBIOTIC DRUG MAT2501
Source text for Eikon: ID:nGNX3YTdbh
Further company coverage: MTNB.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors